These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 7059977)

  • 1. Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928).
    Wheeler GP; Bowdon BJ; Werline JA; Adamson DJ; Temple CG
    Cancer Res; 1982 Mar; 42(3):791-8. PubMed ID: 7059977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
    Waud WR; Leopold WR; Elliott WL; Dykes DJ; Laster WR; Temple CG; Harrison SD; Griswold DP
    Cancer Res; 1990 Jun; 50(11):3239-44. PubMed ID: 2334919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis.
    Bowdon BJ; Waud WR; Wheeler GP; Hain R; Dansby L; Temple C
    Cancer Res; 1987 Mar; 47(6):1621-6. PubMed ID: 3815360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines.
    Wheeler GP; Bowdon BJ; Temple C; Adamson DJ; Webster J
    Cancer Res; 1983 Aug; 43(8):3567-75. PubMed ID: 6861128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
    Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.
    Waud WR; Harrison SD; Temple CG; Griswold DP
    Cancer Chemother Pharmacol; 1992; 29(3):190-4. PubMed ID: 1733551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival.
    Begg AC; Fu KK; Kane LJ; Phillips TL
    Cancer Res; 1980 Jan; 40(1):145-54. PubMed ID: 7349894
    [No Abstract]   [Full Text] [Related]  

  • 10. [Uptake of radioactive precursors for the evaluation of sensitivity of anticancer drugs against cancer cells].
    Ichihashi H; Kondo T
    Gan No Rinsho; 1984 Jul; 30(9 Suppl):1130-8. PubMed ID: 6471419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
    Barret JM; Kruczynski A; Etiévant C; Hill BT
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of new antitumor bifunctional intercalators derived from 7H-pyridocarbazole on sensitive and resistant L 1210 cells.
    Esnault C; Roques BP; Jacquemin-Sablon A; Le Pecq JB
    Cancer Res; 1984 Oct; 44(10):4355-60. PubMed ID: 6467197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
    Deady LW; Rodemann T; Zhuang L; Baguley BC; Denny WA
    J Med Chem; 2003 Mar; 46(6):1049-54. PubMed ID: 12620081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkylphosphonium salts as a new class of antitumor agents.
    Sanyal U; Chatterjee RS; Das SK; Chakraborti SK
    Neoplasma; 1984; 31(2):149-55. PubMed ID: 6717684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance of nocodazole-resistant mutants of CHO cells toward other microtubule inhibitors: similar mode of action of benzimidazole carbamate derivatives and NSC 181928 and TN-16.
    Gupta RS
    Mol Pharmacol; 1986 Aug; 30(2):142-8. PubMed ID: 3736539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents.
    Li WT; Hwang DR; Chen CP; Shen CW; Huang CL; Chen TW; Lin CH; Chang YL; Chang YY; Lo YK; Tseng HY; Lin CC; Song JS; Chen HC; Chen SJ; Wu SH; Chen CT
    J Med Chem; 2003 Apr; 46(9):1706-15. PubMed ID: 12699388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A methodological approach to the prediction of anticancer drug effect in humans.
    Durkin WJ; Ghanta VK; Balch CM; Davis DW; Hiramoto RN
    Cancer Res; 1979 Feb; 39(2 Pt 1):402-7. PubMed ID: 761212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.